Catalyst Pharmaceuticals Valuation
| CPRX Stock | USD 24.35 0.29 1.18% |
At this time, the firm appears to be undervalued. Catalyst Pharmaceuticals shows a prevailing Real Value of $27.39 per share. The current price of the firm is $24.35. Our model approximates the value of Catalyst Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 2.34 B, profit margin of 0.38 %, and Return On Equity of 0.28 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Catalyst Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Catalyst Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Catalyst Pharmaceuticals is based on 3 months time horizon. Increasing Catalyst Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Catalyst Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Catalyst Stock. However, Catalyst Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.35 | Real 27.39 | Target 34.57 | Hype 24.32 | Naive 23.23 |
The intrinsic value of Catalyst Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Catalyst Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Catalyst Pharmaceuticals helps investors to forecast how Catalyst stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Catalyst Pharmaceuticals more accurately as focusing exclusively on Catalyst Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Catalyst Pharmaceuticals' intrinsic value based on its ongoing forecasts of Catalyst Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Catalyst Pharmaceuticals' closest peers.
Catalyst Pharmaceuticals Cash |
|
Catalyst Revenue by Product
Catalyst Pharmaceuticals Total Value Analysis
Catalyst Pharmaceuticals is currently projected to have valuation of 2.34 B with market capitalization of 2.99 B, debt of 3.19 M, and cash on hands of 220.79 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Catalyst Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.34 B | 2.99 B | 3.19 M | 220.79 M |
Catalyst Pharmaceuticals Investor Information
About 88.0% of the company shares are held by institutions such as insurance companies. The book value of Catalyst Pharmaceuticals was currently reported as 7.47. The company had not issued any dividends in recent years. Based on the key indicators related to Catalyst Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Catalyst Pharmaceuticals is performing exceptionally good at this time. It has a great odds to report excellent financial results in March.Catalyst Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Catalyst Pharmaceuticals has an asset utilization ratio of 57.76 percent. This suggests that the Company is making $0.58 for each dollar of assets. An increasing asset utilization means that Catalyst Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Catalyst Pharmaceuticals Profitability Analysis
Based on Catalyst Pharmaceuticals' profitability indicators, Catalyst Pharmaceuticals is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in March. Profitability indicators assess Catalyst Pharmaceuticals' ability to earn profits and add value for shareholders.Net Income | First Reported 2004-03-31 | Previous Quarter 52.1 M | Current Value 52.8 M | Quarterly Volatility 16.5 M |
For Catalyst Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Catalyst Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Catalyst Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Catalyst Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Catalyst Pharmaceuticals over time as well as its relative position and ranking within its peers.
Catalyst Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Catalyst Pharmaceuticals is estimated to be 0.6044 with future projections ranging from a low of 0.53 to a high of 0.64. Catalyst Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at 1.71. Please be aware that the consensus of earnings estimates for Catalyst Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Catalyst Pharmaceuticals Earnings Estimation Breakdown
The calculation of Catalyst Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Catalyst Pharmaceuticals is estimated to be 0.6044 with the future projection ranging from a low of 0.53 to a high of 0.64. Please be aware that this consensus of annual earnings estimates for Catalyst Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.53 Lowest | Expected EPS | 0.64 Highest |
Catalyst Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Catalyst Pharmaceuticals' value are higher than the current market price of the Catalyst Pharmaceuticals stock. In this case, investors may conclude that Catalyst Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Catalyst Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 7 | 82.75% | 0.0 | 0.6044 | 1.71 |
Catalyst Pharmaceuticals Ownership Allocation
Catalyst Pharmaceuticals holds a total of 122.91 Million outstanding shares. The majority of Catalyst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalyst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalyst Pharmaceuticals. Please pay attention to any change in the institutional holdings of Catalyst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Catalyst Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 491.73 M. Net Income was 163.89 M with profit before overhead, payroll, taxes, and interest of 480.67 M.About Catalyst Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Catalyst Pharmaceuticals. We calculate exposure to Catalyst Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Catalyst Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 486.3 M | 510.6 M | |
| Pretax Profit Margin | 0.40 | 0.42 | |
| Operating Profit Margin | 0.36 | 0.37 | |
| Net Profit Margin | 0.30 | 0.31 | |
| Gross Profit Margin | 0.77 | 0.81 |
Catalyst Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 124.9 M | |
| Quarterly Earnings Growth Y O Y | 0.2 | |
| Forward Price Earnings | 11.0988 |
Catalyst Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Catalyst Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Catalyst we look at many different elements of the entity such as Catalyst's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Catalyst Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Catalyst Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Catalyst Pharmaceuticals' worth.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.